Building a national network for lung cancer treatment in Italy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The APOLLO 11 initiative aims to establish a comprehensive network across approximately 48 Italian centers to collect real-world data and conduct translational research on lung cancer. This project focuses on advanced lung cancer patients receiving innovative therapies, including immunotherapy and targeted treatments. By creating a decentralized national database and a virtual biobank, the study seeks to enhance the understanding of prognostic and predictive biomarkers, particularly in the context of immunotherapy. The integration of artificial intelligence will facilitate the development of algorithms for personalized treatment predictions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Provision of signed and dated written informed consent, when applicable, by the patient or legally acceptable representative prior to any mandatory study-specific procedures, sampling, and analyses;
2. Patients must be ≥18 years of age at the time of signing the informed consent;
3. Histologically or cytologically confirmed lung cancer (NSCLC or SCLC) at any stage (I-IV) candidate to receive or already treated with innovative therapies (ICIs, target therapies and next generation therapies).

Exclusion Criteria:

1. Patients who are or will be taking other unapproved antineoplastic therapies concurrently are not eligible.
2. Patients who have not received an oncological systemic innovative therapy at any setting
3. Patients received only local treatments (e.g., only surgery, or only radiotherapy)
4. Patients who received only standard chemotherapy are excluded.
5. Patients who received treatment therapies before 2010 are excluded.

Where it's running

• Fondazione IRCCS Istituto Nazionale dei Tumori
  Milan, Italy Recruiting

Study contacts

• Principal investigator: Carlo Genova — IRCCS Ospedale Policlinico San Martino, Genova
• Study coordinator: Arsela Prelaj, M.D.
• Email: arsela.prelaj@istitutotumori.mi.it
• Phone: +390223903647

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• SI-B036 safety test in advanced and metastatic solid tumors

  This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.

  Recruiting at 4 sites Phase 1 SystImmune Inc. · New Haven, Connecticut and 6 other locations · NCT07857616

• Precise Exercise Regimen for Cancer Care: a small pilot in stage II/III NSCLC

  This pilot tests the PERCC exercise program to see if it’s feasible for adults with stage II–III non-small cell lung cancer who are planned for neoadjuvant therapy and surgery.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07412041

• TNG462 combined with RAS inhibitors or chemotherapy for MTAP‑loss pancreatic and RAS‑mutant lung cancer

  This trial will test whether taking oral TNG462 together with RAS inhibitors or standard chemotherapy is safe and helps people with MTAP‑loss pancreatic cancer or RAS‑mutant non‑small cell lung cancer.

  Recruiting at 18 sites Phase 1/2 Tango Therapeutics, Inc. · Scottsdale, Arizona and 17 other locations · NCT06922591

• Longitudinal study on lung cancer using proteomics analysis

  This study is trying to see if analyzing proteins in blood and tissue samples from lung cancer patients can help doctors better understand the disease and improve treatment outcomes.

  Recruiting The First Affiliated Hospital of Guangzhou Medical University · Guangzhou, Guangdong · NCT06778512

• Evaluating a new CAR T-cell therapy for solid tumors expressing MSLN

  This study is testing a new CAR T-cell therapy to see if it can safely treat adults with solid tumors like colorectal and lung cancer that express a specific protein.

  Recruiting at 12 sites Phase 1/2 A2 Biotherapeutics Inc. · Gilbert, Arizona and 11 other locations · NCT06051695

• Comparing brain radiotherapy timing in lung cancer patients with ALK rearrangements

  This study is testing whether a targeted lung cancer treatment called alectinib works better alone or with brain radiation for patients who have lung cancer with specific genetic changes and brain metastases.

  Recruiting at 3 sites Phase 1/2 Hoosier Cancer Research Network · Stanford, California and 2 other locations · NCT05987644

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.